Abstract
Abstract
Background
Good Clinical Practice guidelines issued in 2016 encourage risk-based approaches to monitoring clinical trials. This study compared current risk assessment and monitoring approaches in UK Clinical Trials Units (CTUs) with the published guidance and makes recommendations for risk-based monitoring in pragmatic trials.
Methods
An online survey of UK Clinical Research Collaboration registered CTUs was administered via email invitation. Forty-nine units were invited, and 23 responded. Respondents were also invited to share copies of risk assessment templates.
Results
Most CTUs reported using remote combined with on-site monitoring. All reported undertaking a risk assessment for Clinical Trials of Investigational Medicinal Products (CTIMPs) and 21 units did so for non-CTIMPs. Most CTIMP risk assessments used MHRA (Medicines and Healthcare products Regulatory Agency) classifications, although some also employed staff judgement. Almost all units based their monitoring on perceived risk level; this number was higher for CTIMPs (n = 22) than for non-CTIMPs (n = 19). In most cases, monitoring plans were produced. More CTUs revisited risk assessments during trials in CTIMPs (n = 21) than in non-CTIMPs (n = 18). Small numbers of units reviewed the monitoring approach always (n = 4) or sometimes (n = 9) and few used the reflection to guide future monitoring.
Conclusions
A high proportion of UK CTUs are using risk-based monitoring in the UK, as recommended by guidelines, for both CTIMPs and non-CTIMPs. This has the potential to make trials more efficient and reduce costs. However, there appears to be a lack of reflection on the value of these revised approaches. There may be a benefit in CTUs collaborating nationally to improve processes for reflection and making changes during the life course of a trial.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Medicine (miscellaneous)
Reference11 articles.
1. International Council for Harmonisation Good Clinical Practice (ICH-GCP) – E6 (R1), 1996. Accessed at:
https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf
. (Last accessed: 11 Jan 2017).
2. Hurley C, Shiely F, Power J, Clarke M, Eustace J, Flanagan E, et al. Risk based monitoring (RBM) tools for clinical trials: a systematic review. Contemp Clin Trials. 2016;51:15–27.
3. Molloy S, Henley P. Monitoring clinical trials: a practical guide. Trop Med Int Health. 2016;21:1602–11.
4. Whitham D, Turzanski J, Bradshaw L, Clarke M, Culliford L, Duley L, et al. Development of a standardised set of metrics for monitoring site performance in multicentre randomised trials: a Delphi study. Trials. 2018;19:557.
5. Tudur Smith C (2016) North West Hub for Trials Methodology Research, Clinical Trial Monitoring: Towards Establishing Best Practice? 2012 Accessed at:
http://www.methodologyhubs.mrc.ac.uk/files/5014/3713/3750/cts_monitoring_htmr_2012.pdf
. (Last accessed: 11 Jan 2017).
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献